Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
232.00+8.63 (+3.86%)
At close: 04:00PM EDT
231.81 -0.19 (-0.08%)
After hours: 05:02PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close223.37
Open225.33
Bid231.85 x 1000
Ask236.00 x 3200
Day's Range224.40 - 233.88
52 Week Range117.58 - 233.88
Volume969,763
Avg. Volume997,419
Market Cap27.846B
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
EPS (TTM)-7.49
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est228.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALNY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Alnylam Pharmaceuticals, Inc.
    Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
Advertisement
Advertisement